Bryce A. Harrison

LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial

Brian Zambrowicz, J Freiman, Phil Brown et al. · Clinical Pharmacology & Therapeutics · 2012 · 235 citations · Full text

A Diels–Alder Macrocyclization Enables an Efficient Asymmetric Synthesis of the Antibacterial Natural Product Abyssomicin C

Christoph W. Zapf, Bryce A. Harrison, CARMEN DRAHL et al. · Angewandte Chemie International Edition · 2005 · 110 citations · Full text

Novel Class of LIM-Kinase 2 Inhibitors for the Treatment of Ocular Hypertension and Associated Glaucoma

Bryce A. Harrison, N. Andrew Whitlock, Michael Voronkov et al. · Journal of Medicinal Chemistry · 2009 · 77 citations · Full text

Hypertension, Ocular Disease, Ophthalmology +14

Novel <scp>l</scp>-Xylose Derivatives as Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes

Nicole C. Goodwin, Ross Mabon, Bryce A. Harrison et al. · Journal of Medicinal Chemistry · 2009 · 76 citations · Full text

Medicinal Chemistry, Diabetes Management, Biochemistry +13

Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes

Nicole C. Goodwin, Zhi‐Ming Ding, Bryce A. Harrison et al. · Journal of Medicinal Chemistry · 2017 · 64 citations · Full text

Medicinal Chemistry, Translational Medicine, Diabetes Management +15